|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li Z, Guo J, Ma Y, Lin Z and Zhang L:
Oncogenic role of MicroRNA-30b-5p in glioblastoma through targeting
proline-rich transmembrane protein 2. Oncol Res. May 17–2017.(Epub
ahead of print).
|
|
3
|
Ding B, Cui B, Gao M, Li Z, Xu C, Fan S
and He W: Knockdown of ras-related protein 25 (Rab25) inhibits the
in vitro cytotoxicity and in vivo antitumor activity of human
glioblastoma multiforme cells. Oncol Res. 25:331–340. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu J, Li W, Liu S, Zheng X, Shi L, Zhang
W and Yang H: Knockdown of collagen triple helix repeat containing
1 (CTHRC1) inhibits epithelial-mesenchymal transition and cellular
migration in glioblastoma cells. Oncol Res. 25:225–232. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arciuch Antico VG, Tedesco L, Fuertes M
and Arzt E: Role of RSUME in inflammation and cancer. FEBS Lett.
589:3330–3335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liberman AC, Druker J, Garcia FA, Holsboer
F and Arzt E: Intracellular molecular signaling. Basis for
specificity to glucocorticoid anti-inflammatory actions. Ann N Y
Acad Sci. 1153:6–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Druker J, Liberman AC, Antunica-Noguerol
M, Gerez J, Paez-Pereda M, Rein T, Iñiguez-Lluhí JA, Holsboer F and
Arzt E: RSUME enhances glucocorticoid receptor SUMOylation and
transcriptional activity. Mol Cell Biol. 33:2116–2127. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carbia-Nagashima A, Gerez J, Perez-Castro
C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F and Arzt E:
RSUME, a small RWD-containing protein, enhances SUMO conjugation
and stabilizes HIF-1alpha during hypoxia. Cell. 131:309–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu Y, Tedesco L, Lucia K, Schlitter AM,
Garcia JM, Esposito I, Auernhammer CJ, Theodoropoulou M, Arzt E,
Renner U and Stalla GK: RSUME is implicated in tumorigenesis and
metastasis of pancreatic neuroendocrine tumors. Oncotarget.
7:57878–57893. 2016.PubMed/NCBI
|
|
10
|
Fuertes M, Gerez J, Haedo M, Giacomini D,
Páez-Pereda M, Labeur M, Stalla GK and Arzt E: Cytokines and genes
in pituitary tumorigenesis: RSUME role in cell biology. Front Horm
Res. 38:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shan B, Gerez J, Haedo M, Fuertes M,
Theodoropoulou M, Buchfelder M, Losa M, Stalla GK, Arzt E and
Renner U: RSUME is implicated in HIF-1-induced VEGF-A production in
pituitary tumour cells. Endocr Relat Cancer. 19:13–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gerez J, Tedesco L, Bonfiglio JJ, Fuertes
M, Barontini M, Silberstein S, Wu Y, Renner U, Páez-Pereda M,
Holsboer F, et al: RSUME inhibits VHL and regulates its tumor
suppressor function. Oncogene. 34:4855–4866. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan YH, Zhu XG, WU MJ, Chai Y, YE MH,
Xi-Ao B and Wu L: Effects of lentivirus-mediated RWDD3 silencing on
proliferation and invasion of human glioma U251 cells. Chin J
Pathophysiol. 31:1550–1556. 2015.
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katase N, Nishimatsu SI, Yamauchi A,
Yamamura M, Terada K, Itadani M, Okada N, Hassan NMM, Nagatsuka H,
Ikeda T, et al: DKK3 overexpression increases malignant properties
of head and neck squamous cell carcinoma cells. Oncol Res.
26:45–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao P, Guan HT, Dai ZJ, Ma YG, Liu XX and
Wang XJ: Knockdown of SPOCK1 inhibits the proliferation and
invasion in colorectal cancer cells by suppressing the PI3K/Akt
pathway. Oncol Res. 24:437–445. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu W, Hu Q, Nie E, Yu T, Wu Y, Zhi T,
Jiang K, Shen F, Wang Y, Zhang J and You Y: Hypoxia induces H19
expression through direct and indirect Hif-1α activity, promoting
oncogenic effects in glioblastoma. Sci Rep. 7:450292017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gabriely G, Wheeler MA, Takenaka MC and
Quintana FJ: Role of AHR and HIF-1α in glioblastoma metabolism.
Trends Endocrinol Metab. 28:428–436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu M, Wang D and Li N: MicroRNA-20b
downregulates HIF-1α and Inhibits the proliferation and invasion of
osteosarcoma cells. Oncol Res. 23:257–266. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Yang C, Wang K, Liu X and Liu Q:
MicroRNA-33b inhibits the proliferation and migration of
osteosarcoma cells via targeting hypoxia-inducible factor-1α. Oncol
Res. 25:397–405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu F, Lin B, Liu X, Zhang W, Zhang E, Hu
L, Ma Y, Li X and Tang X: ERK signaling pathway is involved in
HPV-16 E6 but not E7 oncoprotein-induced HIF-1α protein
accumulation in NSCLC cells. Oncol Res. 23:109–118. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang F, Cai F, Shi R, Wei JN and Wu XT:
Hypoxia regulates sumoylation pathways in intervertebral disc
cells: Implications for hypoxic adaptations. Osteoarthritis
Cartilage. 24:1113–1124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gerez J, Fuertes M, Tedesco L, Silberstein
S, Sevlever G, Paez-Pereda M, Holsboer F, Turjanski AG and Arzt E:
In silico structural and functional characterization of the RSUME
splice variants. PLoS One. 8:e577952013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue Q, Cao L, Chen XY, Zhao J, Gao L, Li
SZ and Fei Z: High expression of MMP9 in glioma affects cell
proliferation and is associated with patient survival rates. Oncol
Lett. 13:1325–1330. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Y, Zhang X, Wang L, Ji Z, Xie M, Zhou
X, Liu Z, Shi H and Yu R: Loss of SH3GL2 promotes the migration and
invasion behaviours of glioblastoma cells through activating the
STAT3/MMP2 signalling. J Cell Mol Med. 21:2685–2694. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miao Y, Lu M, Yan Q, Li S and Feng Y:
Inhibition of proliferation, migration, and invasion by knockdown
of pyruvate kinase-M2 (PKM2) in ovarian cancer SKOV3 and OVCAR3
cells. Oncol Res. 24:463–475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Amar S, Minond D and Fields GB: Clinical
implications of compounds designed to inhibit ECM-modifying
metalloproteinases. Proteomics. 17(23–24)2017.PubMed/NCBI
|
|
28
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ramezani S, Vousooghi N, Kapourchali
Ramezani F and Joghataei MT: Perifosine enhances
bevacizumab-induced apoptosis and therapeutic efficacy by targeting
PI3K/AKT pathway in a glioblastoma heterotopic model. Apoptosis.
22:1025–2034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP,
To ST and Li WP: Recent advances in the use of PI3K inhibitors for
glioblastoma multiforme: Current preclinical and clinical
development. Mol Cancer. 16:1002017. View Article : Google Scholar : PubMed/NCBI
|
